Prasugrel Loading Dose
ApprovedSmall molecule
Daiichi SankyoPrasugrel Loading Dose is one of 71 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.
2
Indications
2
Total Trials
0
Active Trials
70
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
232 competitors in Myocardial Infarction
#DrugCompanyPhaseTrials
1Lovenox
SanofiPhase 3
Eliquis
Bristol-Myers SquibbPhase 3
Aranesp
AmgenPhase 3
PROCRIT
WWim Janssens
Phase 3
Tekturna
Tibotec Pharmaceuticals, IrelandPhase 3
Ticlid
RochePhase 3
Tissue Plasminogen Activator
NNeuroscience Trials Australia
Phase 3
Stem Cells
KKang Stem Biotech Co., Ltd.
Phase 3
Actilyse
Boehringer IngelheimPhase 3
Prasugrel Loading Dose
Daiichi SankyoApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Prasugrel Loading Dose. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company